63 related articles for article (PubMed ID: 9329584)
21. Diagnostic value of skeletal AP and PSA with respect to skeletal scintigram in patients with prostatic disease.
Oremek GM; Kramer W; Seiffert UB; Jonas D
Anticancer Res; 1997; 17(4B):3035-6. PubMed ID: 9329594
[TBL] [Abstract][Full Text] [Related]
22. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
23. Serum concentrations of transforming growth factor-beta 1 in patients with benign and malignant prostatic diseases.
Wolff JM; Fandel TH; Borchers H; Jakse G
Anticancer Res; 1999; 19(4A):2657-9. PubMed ID: 10470214
[TBL] [Abstract][Full Text] [Related]
24. Prostate cancer detection by prostate-specific antigen-related parameters.
Segawa N; Gohji K; Iwamoto Y; Ueda H; Katsuoka Y
Hinyokika Kiyo; 2003 Jul; 49(7):405-10. PubMed ID: 12968483
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
26. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.
Berruti A; Dogliotti L; Bitossi R; Fasolis G; Gorzegno G; Bellina M; Torta M; Porpiglia F; Fontana D; Angeli A
J Urol; 2000 Oct; 164(4):1248-53. PubMed ID: 10992374
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
28. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
29. Rationale for using serum prostate-specific antigen (PSA) level and PSA density (PSAD) to detect prostatic malignancy in a country with low prostate cancer incidence.
Rahardjo D; Kamil ST; Pakasi LS
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():563-70. PubMed ID: 10895211
[TBL] [Abstract][Full Text] [Related]
30. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
[TBL] [Abstract][Full Text] [Related]
31. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men.
Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M
Urol J; 2009; 6(3):182-8. PubMed ID: 19711272
[TBL] [Abstract][Full Text] [Related]
32. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
33. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
34. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
36. Serum bone alkaline phosphatase in the follow-up of skeletal metastases.
Zaninotto M; Secchiero S; Rubin D; Sciacovelli L; Trovò M; Bortolus R; Plebani M
Anticancer Res; 1995; 15(5B):2223-8. PubMed ID: 8572629
[TBL] [Abstract][Full Text] [Related]
37. [Levels of prostate-specific antigen, acid phosphatase, alkaline phosphatase and pain in the prediction of bone metastases in patients with newly diagnosed prostatic carcinoma].
Kliment J; Eliás B; Svihra J
Rozhl Chir; 1994 Sep; 73(6):300-2. PubMed ID: 7536351
[TBL] [Abstract][Full Text] [Related]
38. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications.
Oesterling JE
Urol Clin North Am; 1993 Nov; 20(4):705-11. PubMed ID: 7505979
[TBL] [Abstract][Full Text] [Related]
39. Levels of prostate specific antigen that predict skeletal spread in prostate cancer.
Pantelides ML; Bowman SP; George NJ
Br J Urol; 1992 Sep; 70(3):299-303. PubMed ID: 1384921
[TBL] [Abstract][Full Text] [Related]
40. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Cooper EH; Whelan P; Purves D
Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]